Journal
PHARMACOGENOMICS
Volume 19, Issue 2, Pages 105-112Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0153
Keywords
childhood ALL; dihydrofolate reductase polymorphisms; treatment outcome
Categories
Funding
- Leukemia Lymphoma Society of Canada
- Charles Bruneau Foundation
- Associazione Italiana per la Ricerca sul Cancro
Ask authors/readers for more resources
Aim: We have previously reported an association of dihydrofolate reductase promoter polymorphisms with reduced event-free survival in childhood acute lymphoblastic leukemia (ALL) patients treated with Dana Farber Cancer Institute protocol. Here, we assessed whether these associations are applicable to other protocol, based on different methotrexate doses. Methods: Genotypes for six tag polymorphisms and resulting haplotypes were analyzed for an association with ALL outcome. Results: The association was found with the polymorphisms A-680C, A-317G and C-35T in high-risk group patients. Carriers of haplotype *1 had a remarkably higher risk of events compared with noncarriers and a lower probability of event-free survival (21.4 vs 81.3%). Conclusion: The role of DHFR variants in predicting the outcome of childhood ALL extends beyond single-treatment protocol and can be useful biomarker in personalizing treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available